ATE244305T1 - Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels - Google Patents
Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegelsInfo
- Publication number
- ATE244305T1 ATE244305T1 AT96913912T AT96913912T ATE244305T1 AT E244305 T1 ATE244305 T1 AT E244305T1 AT 96913912 T AT96913912 T AT 96913912T AT 96913912 T AT96913912 T AT 96913912T AT E244305 T1 ATE244305 T1 AT E244305T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- bcl
- modulating
- survival rate
- cell survival
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43551895A | 1995-05-04 | 1995-05-04 | |
US08/481,739 US6143291A (en) | 1995-05-04 | 1995-06-07 | Methods for modulating T cell survival by modulating bcl-XL protein level |
PCT/US1996/006203 WO1996034956A1 (en) | 1995-05-04 | 1996-05-02 | Methods for modulating t cell survival by modulating bcl-xl protein level |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE244305T1 true ATE244305T1 (de) | 2003-07-15 |
Family
ID=27030576
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03014974T ATE393634T1 (de) | 1995-05-04 | 1996-05-02 | Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels |
AT96913912T ATE244305T1 (de) | 1995-05-04 | 1996-05-02 | Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03014974T ATE393634T1 (de) | 1995-05-04 | 1996-05-02 | Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0826043B1 (de) |
JP (2) | JPH11504814A (de) |
AT (2) | ATE393634T1 (de) |
AU (1) | AU5673496A (de) |
CA (1) | CA2220012C (de) |
DE (1) | DE69628921T2 (de) |
WO (1) | WO1996034956A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2780891A1 (fr) * | 1998-07-10 | 2000-01-14 | Univ Paris Curie | Echange de lymphocytes t |
WO2000026391A2 (en) * | 1998-10-30 | 2000-05-11 | University Of Nebraska-Lincoln | Trans-species transfer of apoptotic genes and transgenic plants developed thereby |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
JP2004521867A (ja) | 2000-10-27 | 2004-07-22 | イミュノ−アールエックス, インコーポレイテッド | 免疫抑制された患者のためのワクチン免疫療法 |
CA2706445C (en) * | 2007-11-28 | 2019-07-23 | Irx Therapeutics, Inc. | Production of apoptosis-resistant t-lymphocytes for use in cancer therapy |
WO2010132867A1 (en) | 2009-05-15 | 2010-11-18 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
-
1996
- 1996-05-02 WO PCT/US1996/006203 patent/WO1996034956A1/en active IP Right Grant
- 1996-05-02 DE DE69628921T patent/DE69628921T2/de not_active Expired - Lifetime
- 1996-05-02 JP JP8533512A patent/JPH11504814A/ja active Pending
- 1996-05-02 AT AT03014974T patent/ATE393634T1/de not_active IP Right Cessation
- 1996-05-02 AT AT96913912T patent/ATE244305T1/de not_active IP Right Cessation
- 1996-05-02 AU AU56734/96A patent/AU5673496A/en not_active Abandoned
- 1996-05-02 EP EP96913912A patent/EP0826043B1/de not_active Expired - Lifetime
- 1996-05-02 CA CA002220012A patent/CA2220012C/en not_active Expired - Fee Related
-
2007
- 2007-10-25 JP JP2007277882A patent/JP2008101003A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH11504814A (ja) | 1999-05-11 |
WO1996034956A1 (en) | 1996-11-07 |
AU5673496A (en) | 1996-11-21 |
ATE393634T1 (de) | 2008-05-15 |
DE69628921D1 (de) | 2003-08-07 |
EP0826043A1 (de) | 1998-03-04 |
DE69628921T2 (de) | 2004-04-22 |
CA2220012A1 (en) | 1996-11-07 |
EP0826043B1 (de) | 2003-07-02 |
JP2008101003A (ja) | 2008-05-01 |
CA2220012C (en) | 2007-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535448D1 (de) | Vorrichtung zur Unterdrückung von stimulierter Brillouin Streuung | |
DE69713499D1 (de) | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung | |
AU5301201A (en) | Methods of modulating hair growth | |
ES2053897T3 (es) | Un metodo para estabilizar factores de coagulacion de la sangre. | |
ATE244305T1 (de) | Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels | |
ATE232191T1 (de) | Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen | |
NO20010389D0 (no) | Modulering av multippel linje-kinaseproteiner | |
DE69325029D1 (de) | Verwendung der il-10 zur verhinderung des insulin-abhängigen diabetes mellitus | |
ATE293964T1 (de) | Zusammensetzungen und verfahren zur behinderung der entladung von nematokyste | |
ATE499445T1 (de) | Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b | |
DE3872632T2 (de) | Vorrichtung zur diebstahlsicherung von autostereoanlagen. | |
ATE274322T1 (de) | Verfahren und vorrichtung zur eröffnung von eiern | |
DE69923559D1 (de) | Methoden zur inhibierung von helicobacter pylori | |
DE69715013T2 (de) | S-alkylisothiouronium-derivate enthaltende pharmazeutische zusammensetzungen | |
DE69427290D1 (de) | Verfahren zur induktion des todes von tumorzellen | |
DE69420960D1 (de) | Mittel zur Verhinderung von Belagbildung, Zusammensetzungen dieses enthaltend und Anwendungsverfahren für Polymerisationsprozesse | |
CH684863GA3 (de) | Verfahren und Einrichtung zur Prüfung der Wasserdichtigkeit von Gehäusen. | |
DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
DE69016249T2 (de) | Verfahren zur elektrochemischen Behandlung von Schwefelwasserstoff enthaltendem Gas. | |
TR199903118A2 (xx) | Organosilanpolis�lfanlar i�eren kau�uk kar���mlar�. | |
DE69918302D1 (de) | Verfahren zur inaktivierung von viren | |
DE59402382D1 (de) | Verfahren zur bekämpfung von lepidopteren mit (e,z)8-tetradecenylacetat, und verfahren zu dessen herstellung | |
DE29623414U1 (de) | Vorrichtung zur Brandbekämpfung von Schießpulverablagerungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |